Drug
Abilify Mycite
Abilify Mycite: highest development phase Post-Market, developed by Otsuka. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| ABILIFY MYCITE NCT03881449 | Post-Market | Schizophrenia |
Latest
No recent events.
Follow Abilify Mycite on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.